<DOC>
	<DOCNO>NCT02435563</DOCNO>
	<brief_summary>Ticagrelor new generation antiplatelet agent high efficacy compare clopidogrel prasugrel treatment patient moderate high ischemic risk . Ticagrelor active hepatic metabolism CYP3A generate also active metabolite . Because remarkable progress HIV therapies number old age patient rise , require adequate cardiovascular treatment . Since frontline HIV therapy include ritonavir , strong inhibitor CYP3A enzyme , ticagrelor contraindicate patient expect interaction bleed risk . A low efficacy clopidogrel prasugrel , pro-drugs , presence ritonavir already demonstrate . Therefore , administration lower dose ticagrelor may good alternative HIV patient order lessen impact pharmacokinetic interaction . The aim study adjust dose ticagrelor case co-treatment ritonavir achieve pharmacokinetic profile administer alone use physiologically-based pharmacokinetic ( PBPK ) model . As first step , pharmacokinetic ( PK ) model ticagrelor active metabolite create base available vitro vivo parameter healthy volunteer . An open-label , 2 session cross study conduct 20 healthy male volunteer Clinical Research Center ( CRC ) Geneva University Hospitals ( HUG ) . During first session clinical trial , single dose 180 mg ticagrelor administer volunteer obtain pharmacokinetic data fit model optimization . Thereafter simulated trial Simcyp® simulator presence single dose 100 mg ritonavir allow evaluate impact CYP3A inhibition concentration-time profile ticagrelor active metabolite . The necessary dose ticagrelor minimize magnitude interaction calculate . This new dose co-administered ritonavir volunteer second session clinical trial . The purpose obtain PK profile single dose 180 mg ticagrelor administer alone adapt dose ticagrelor co-administered single dose 100 mg ritonavir . Moreover , pharmacodynamic effect ticagrelor measure session clinical trial use two specific platelet function test : VAsodilator-Stimulated Phosphoprotein assay ( VASP ) VerifyNow® P2Y12 . With PK profile , pharmacodynamic activity expect . The modulation activity CYP3A P-gp ritonavir also monitor use micro dose midazolam fexofenadine probe substrate . The purpose study use Simcyp® Simulator mechanistic PBPK model broaden application field ticagrelor , especially HIV patient . Since PK model often create clinical observation , prospective aspect study particular value model first create applied unknown clinical scenario .</brief_summary>
	<brief_title>Dose Adaptation Offset Interaction Between Ticagrelor Ritonavir Population-based PK Modeling</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male volunteer Aged 18 60 year BMI 18 27 Understanding French language able give inform consent . Hypersensitivity ticagrelor ritonavir constituent tablet Concomitant diseases Smokers ( &gt; 20 cigarette per day ) Intake drug food ( grapefruit ) metabolize affect CYP3A Pglycoprotein activity within last 10 day Pathologies drug associate increase bleeding risk aspirin , nonsteroidal antiinflammatory drug , steroid serotonin reuptake inhibitor Bleeding familial history antecedent hemorrhagic disease Previous active gastrointestinal ulcer Alteration hepatic test ( ASAT &gt; 100 U/l , ALAT &gt; 100 U/l , GGT &gt; 80 U/l , BILI &gt; 50 μmol/l )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>cardiovascular agent</keyword>
	<keyword>drug interaction</keyword>
</DOC>